Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2444)	10/22/2008 5:14:25 PM
From: Jibacoa	Respond to of 3722

NKTR was among the few closing on the green today.<g> bigcharts.marketwatch.com It was helped by the announcement yesterday that Novartis has agreed to acquire some pulmonary delivery assets, technology, & intellectual property for $115M in cash. They said that the agreement will allow them to focus on the development of therapeutics using their PEGylation & conjugate chemistry-based drug development.Adding that "It is a perfect example of our ability to monetize assets that had little future value for Nektar." The agreement also transfers to Novartis approximately 140 NKTR personnel NKTR will retain ownership of its Bayer HealthCare-partnered program NKTR-061,which is scheduled to enter PIII by year-end, & royalties to Ciprofloxacin inhaled powder, also partnered with Bayer HealthCare. Likewise, NKTR will retain NKTR-063, scheduled to enter a PII in the U.S. early next year. Bernard